Pfizer's (PFE) Palbociclib Has $5 Billion Potential
Tweet Send to a Friend
This morning Pfizer Inc. (NYSE: PFE) announced its investigational compound palbociclib (PD-0332991), an oral and selective inhibitor of cyclin dependent ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE